Literature DB >> 28631964

Evidence-based assessment of ADHD diagnosis in children and adolescents.

Xuechun Zhou1, Cecil R Reynolds2, Jianjun Zhu1, Randy W Kamphaus3, Ou Zhang1.   

Abstract

This study illustrates the accuracy and efficiency of using an evidence-based assessment (EBA) strategy for diagnosis of attention-deficit/hyperactivity disorder (ADHD) by integrating the scale scores obtained on BASC-3 teacher and parent rating scales. The examined process used empirical diagnostic likelihood ratios (DLRs) derived from a sample of children with ADHD (N = 339) matched on demographic characteristics from the normative sample. The results show that behavioral scales of executive functioning and functional communication provided incremental utility in ADHD diagnosis. With a revised probability of .80 or higher as the diagnostic criterion, teachers, and parents positively diagnosed 70% and 94% of the ADHD cases respectively. The EBA approach was efficient, with four scales on average used to reach the proposed posterior probability for final diagnosis. Finally, teachers and parents demonstrated a high agreement with respect to the diagnosis results and scales used for the diagnosis.

Entities:  

Keywords:  ADHD; BASC-3; clinical diagnosis; evidence-based assessment; incremental utility

Mesh:

Year:  2017        PMID: 28631964     DOI: 10.1080/21622965.2017.1284661

Source DB:  PubMed          Journal:  Appl Neuropsychol Child        ISSN: 2162-2965            Impact factor:   1.493


  2 in total

1.  A pupil size, eye-tracking and neuropsychological dataset from ADHD children during a cognitive task.

Authors:  Daniel Rojas-Líbano; Gabriel Wainstein; Ximena Carrasco; Francisco Aboitiz; Nicolás Crossley; Tomás Ossandón
Journal:  Sci Data       Date:  2019-04-11       Impact factor: 6.444

2.  Differentiating Boys with ADHD from Those with Typical Development Based on Whole-Brain Functional Connections Using a Machine Learning Approach.

Authors:  Yunkai Sun; Lei Zhao; Zhihui Lan; Xi-Ze Jia; Shao-Wei Xue
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-10       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.